Lynparza (olaparib) : novo tarčno zdravilo pri raku jajčnikov

Izpis gradiva
A+ | A- | | SLO | ENG

Naslov:	Lynparza (olaparib) : novo tarčno zdravilo pri raku jajčnikov
Avtorji:	ID Škof, Erik (Avtor) ID Krajc, Mateja (Avtor)
Datoteke:	PDF - Predstavitvena datoteka, prenos (455,09 KB) MD5: 37B328CD7E07A7A79800651CD6B55CD1 PID: 20.500.12556/dirros/0a8348db-a511-405e-9e78-3dea12aebdba
Jezik:	Slovenski jezik
Tipologija:	1.04 - Strokovni članek
Organizacija:	OI - Onkološki inštitut Ljubljana
Ključne besede:	rak jajčnikov, tarčna zdravila, kemoterapija, dedni raki
Status publikacije:	Objavljeno
Verzija publikacije:	Objavljena publikacija
Leto izida:	2016
Št. strani:	str. 12-14
Številčenje:	Letn. 20, št. 1
PID:	20.500.12556/DiRROS-8145
UDK:	618.1
ISSN pri članku:	1408-1741
COBISS.SI-ID:	2416763
Avtorske pravice:	by Authors
Datum objave v DiRROS:	03.01.2018
Število ogledov:	4479
Število prenosov:	1035
Metapodatki:
:	Kopiraj citat

Objavi na:

Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Licenca:	CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna

Povezava:	http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:	To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:	03.01.2018

Jezik:	Angleški jezik
Naslov:	Lynparza (olaparib) : New Mmedicine for targeted therapy of ovarian cancer
Povzetek:	A new medicine for targeted treatment of patients with recurring serous ovarian or primary peritoneal serous carcinoma (PPSC), who have a mutation of BRCA1/2 genes (somatic mutation), was recently registered in the EU – LynparzaTM (olaparib). Olaparib was registered based on a subanalysis of a study in phase II (9), in which patients with BRCA1/2 gene mutation who received olaparib lived 7 months longer without the disease progressing than patients that were not administered this medicine (11 months vs. 4 months); the difference was statistically relevant (HR 0.18; p < 0.00001). There were no differences in total survival of patients. Olaparib is an oral medication in capsules, so patients can take it at home. The available data shows that the most frequent side effects were nausea and fatigue. 25% of patients took olaparib for two years or more and the therapy was rarely discontinued due to side effects (only 9% of patients), which shows that patients usually tolerate olaparib well, which is a great advantage compared to chemotherapy, which was so far the only available treatment for recurring ovarian cancer (9).

niGradiv

Nazaj